8-K – 2026-07-09 – tm2620110d1_8k.htm

false
0002046386

0002046386

2026-07-07
2026-07-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM  8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report
(Date of earliest event reported) : July 7, 2026

 

 

 

Medline Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware
001-43022
33-1845288

(State or other jurisdiction of

incorporation)
(Commission File Number)
(IRS Employer Identification Number)

 

3 Lakes Drive

Northfield ,
IL 60093

(Address of principal executive offices, including
zip code)

 

( 847 ) 949-5500

(Registrant's telephone number, including area
code)

 

Not Applicable

(Former name or former address, if changed since
last report)

 

 

 

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class
Trading Symbol
Name of each exchange on which registered

Class A common stock, par value $0.0001 per share
MDLN
Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 7, 2026, Stephen L. Miller, Chief
Operating Officer of Medline Inc. (the “ Company ”), notified the Company that he would retire from his role, effective
August 30, 2026, for health-related reasons. The Company is launching a search for his successor.

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

 

Date: July 9, 2026

 

 
MEDLINE INC.

 
 
 

 
By:
/s/
Alex M. Liberman

 
 
Name:
Alex
M. Liberman

 
 
Title:
Chief
Legal Officer